Revenue
2019
2020
2021
2022
2023
2024
2025
Pliant Therapeutics, Inc. (PLRX)
Price$1.16Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.6M | $9.7M | $7.6M | $41.8M | $57.1M |
| Research & development | $109.2M | $169.3M | $127.8M | $96.9M | $77.5M | $66.2M | $47.4M |
| Operating expenses | $156.4M | $228.4M | $185.7M | $136.9M | $105.1M | $83.5M | $58.3M |
| Operating income | −$156.4M | −$228.4M | −$184.1M | −$127.2M | −$97.5M | −$41.6M | −$1.2M |
| Operating margin | — | — | −11,654.75% | −1,313.37% | −1,288.10% | −99.59% | −2.16% |
| EBITDA | −$154.7M | −$226.2M | −$182.3M | −$125.4M | −$96.0M | −$40.3M | −$118,000 |
| EBITDA margin | — | — | −11,538.23% | −1,294.55% | −1,267.83% | −96.46% | −0.21% |
| Net income | −$149.3M | −$210.3M | −$161.3M | −$123.3M | −$97.3M | −$41.5M | −$631,000 |
| Net profit margin | — | — | −10,211.14% | −1,273.32% | −1,284.51% | −99.32% | −1.11% |
| Basic EPSper basic share | -$2.43 | -$3.47 | -$2.75 | -$2.94 | -$2.71 | -$1.95 | -$4.22 |
| Diluted EPSper diluted share | -$2.43 | -$3.47 | -$2.75 | -$2.94 | -$2.71 | -$1.95 | -$4.22 |
Owners
Reported shareholders
9.92%of listed shares
TANG CAPITAL MANAGEMENT LLC6.14M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
TANG CAPITAL MANAGEMENT LLC | 9.92%6.14M shares |
ADAR1 Capital Management, LLC | 8.90%5.51M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.94%2.44M shares |
ACADIAN ASSET MANAGEMENT LLC | 3.90%2.42M shares |
TWO SIGMA INVESTMENTS, LP | 3.65%2.26M shares |
CITADEL ADVISORS LLC | 3.46%2.14M shares |
RENAISSANCE TECHNOLOGIES LLC | 3.31%2.05M shares |
Monaco Asset Management SAM | 3.13%1.94M shares |
Lynx1 Capital Management LP | 2.90%1.8M shares |
BML Capital Management, LLC | 2.50%1.55M shares |
Prosight Management, LP | 2.21%1.37M shares |
Peapod Lane Capital LLC | 2.11%1.31M shares |
Woodline Partners LP | 2.09%1.3M shares |
BlackRock, Inc. | 1.86%1.15M shares |
Ikarian Capital, LLC | 1.61%1M shares |
Coulie Bernard | ≈1.48%914.92K shares |
Eversept Partners, LP | 1.44%891.43K shares |
MARSHALL WACE, LLP | 1.35%835.12K shares |
Redmile Group, LLC | 1.25%772.13K shares |
JPMORGAN CHASE & CO | 1.10%681.65K shares |
Percentages use 61.92M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 20, 2026Form 4 · 10b5-1 | Cummings Keith LamontChief Financial Officer | SellCommon Stock | 24.0K | $1.28 | $30.7K | 297.2K |
| Jan 20, 2026Form 4 · 10b5-1 | Cheung LilyChief Human Resource Officer | SellCommon Stock | 7.5K | $1.28 | $9.6K | 44.8K |
| Jan 20, 2026Form 4 · 10b5-1 | Coulie BernardPresident and CEO | SellCommon Stock | 89.4K | $1.28 | $114.4K | 505.6K |
| Jan 20, 2026Form 4 · 10b5-1 | Kuo MinnieChief Operating Officer | SellCommon Stock | 6.9K | $1.28 | $8.9K | 37.8K |
| Jan 22, 2025Form 4 · 10b5-1 | Ouimette MikeGeneral Counsel & Corp. Sec'y | SellCommon Stock | 10.2K | $10.99 | $112.4K | 70.5K |